Cargando…

An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial

INTRODUCTION: Arginase-1 (ARG1) and Programed death ligand-1 (PD-L1) play a vital role in immunosuppression in myeloproliferative neoplasms (MPNs) and directly inhibit T-cell activation and proliferation. We previously identified spontaneous T-cell responses towards PD-L1 and ARG1 derived peptide ep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grauslund, Jacob Handlos, Holmström, Morten Orebo, Martinenaite, Evelina, Lisle, Thomas Landkildehus, Glöckner, Hannah Jorinde, El Fassi, Daniel, Klausen, Uffe, Mortensen, Rasmus E. J., Jørgensen, Nicolai, Kjær, Lasse, Skov, Vibe, Svane, Inge Marie, Hasselbalch, Hans Carl, Andersen, Mads Hald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996128/ https://www.ncbi.nlm.nih.gov/pubmed/36911725 http://dx.doi.org/10.3389/fimmu.2023.1117466

Ejemplares similares

Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow
por: Holmström, Morten Orebo, et al.
Publicado: (2023)

Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies
por: Klausen, Uffe, et al.
Publicado: (2018)

Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms
por: Handlos Grauslund, Jacob, et al.
Publicado: (2021)

Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms
por: Holmström, Morten Orebo, et al.
Publicado: (2020)

Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV
por: Klausen, Uffe, et al.
Publicado: (2022)

Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression
por: Carnaz Simões, Ana Micaela, et al.
Publicado: (2022)

Corrigendum: Patients with myeloproliferative neoplasms harbor high frequencies of CD8 T cell-platelet aggregates associated with T cell suppression
por: Simões, Ana Micaela Carnaz, et al.
Publicado: (2022)

High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals
por: Holmström, Morten O., et al.
Publicado: (2019)

Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells
por: Weis-Banke, Stine Emilie, et al.
Publicado: (2022)

Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment
por: Kjær, Lasse, et al.
Publicado: (2016)

Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms
por: Hasselbalch, Hans Carl, et al.
Publicado: (2023)

The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines
por: Weis-Banke, Stine Emilie, et al.
Publicado: (2020)

Lower CXCR3 expression in both patients with neovascular AMD and advanced stages of chronic myeloproliferative blood cancers
por: Liisborg, Charlotte, et al.
Publicado: (2022)

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
por: Hasselbalch, Hans Carl, et al.
Publicado: (2018)

Retinal drusen in patients with chronic myeloproliferative blood cancers are associated with an increased proportion of senescent T cells and signs of an aging immune system
por: Liisborg, Charlotte, et al.
Publicado: (2021)

Myeloproliferative blood cancers as a human neuroinflammation model for development of Alzheimer’s disease: evidences and perspectives
por: Hasselbalch, Hans C., et al.
Publicado: (2020)

Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial
por: Jørgensen, Nicolai Grønne, et al.
Publicado: (2020)

Serum levels of IL-4, IL-13 and IL-33 in patients with age-related macular degeneration and myeloproliferative neoplasms
por: Gotfredsen, Kathrine, et al.
Publicado: (2023)

Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy
por: Mortensen, Rasmus Erik Johansson, et al.
Publicado: (2023)

Healthy Donors Harbor Memory T Cell Responses to RAS Neo-Antigens
por: Holmström, Morten Orebo, et al.
Publicado: (2020)

Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial
por: Lorentzen, Cathrine Lund, et al.
Publicado: (2022)

Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study
por: Jørgensen, Nicolai Grønne, et al.
Publicado: (2021)

Patients with MPNs and retinal drusen show signs of complement system dysregulation and a high degree of chronic low-grade inflammation
por: Liisborg, Charlotte, et al.
Publicado: (2021)

Whole Blood Transcriptional Profiling Reveals Deregulation of Oxidative and Antioxidative Defence Genes in Myelofibrosis and Related Neoplasms. Potential Implications of Downregulation of Nrf2 for Genomic Instability and Disease Progression
por: Hasselbalch, Hans Carl, et al.
Publicado: (2014)

Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms
por: Skov, Vibe, et al.
Publicado: (2022)

Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms
por: Kjær, Lasse
Publicado: (2020)

HSC Niche Dynamics in Regeneration, Pre-malignancy, and Cancer: Insights From Mathematical Modeling
por: Pedersen, Rasmus Kristoffer, et al.
Publicado: (2022)

Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives
por: Hasselbalch, Hans, et al.
Publicado: (2022)

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2021)

Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2022)

Elevated levels of oxidized nucleosides in individuals with the JAK2V617F mutation from a general population study
por: Sørensen, Anders L., et al.
Publicado: (2021)

JAK2V617F mutation is highly prevalent in patients with ischemic stroke: a case-control study
por: Kristiansen, Marie Hvelplund, et al.
Publicado: (2023)

First in man study: Bcl-Xl_42-CAF(®)09b vaccines in patients with locally advanced prostate cancer
por: Mørk, Sofie Kirial, et al.
Publicado: (2023)

Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment
por: Bendtsen, Simone Kloch, et al.
Publicado: (2022)

Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis
por: Kjær, Lasse, et al.
Publicado: (2023)

Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development
por: Andersen, Morten, et al.
Publicado: (2017)

Mediators of Inflammation in Myeloproliferative Neoplasms: State of the Art
por: Hermouet, Sylvie, et al.
Publicado: (2015)

Transcriptional Profiling of Whole Blood Identifies a Unique 5-Gene Signature for Myelofibrosis and Imminent Myelofibrosis Transformation
por: Hasselbalch, Hans Carl, et al.
Publicado: (2014)

Myeloproliferative neoplasms in five multiple sclerosis patients()
por: Thorsteinsdottir, Sigrun, et al.
Publicado: (2013)

A novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon‐alpha2
por: Dam, Marc J. B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ljcrogsbd3o74oihu8bfale2s8